| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. | TNX-102 SL - (PREVAIL) | Fibromyalgia-type Long COVID | Phase 2 | Data Released | sublingual | COVID-19 |
| Tonix Pharmaceuticals Holding Corp. | TNX-601 ER - (UPLIFT) | Major depressive disorder (MDD) | Phase 2 | Trial Discontinued | oral | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-1300 | Cocaine intoxication | Phase 2 | Trial Planned | Intravenous | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-1900 - (PREVENTION) | Migraine | Phase 2 | Data Released | Intranasal | Neurology |
| Tonix Pharmaceuticals Holding Corp. | Tonmya (TNX-102 SL) | Alcohol Use Disorder | Phase 2 | Ongoing | Sublingual | Psychiatric |
| Tonix Pharmaceuticals Holding Corp. | TNX-201 | Episodic tension-type headache | Phase 2 | Trial Discontinued | Oral | Neurology |
| Tourmaline Bio Inc. | FCR001 - (FREEDOM-1) | Transplanted Organ Rejection | Phase 3 | Trial Discontinued | Intravenous | Immunosuppressant |
| Tourmaline Bio Inc. | TOUR006 - (TRANQUILITY) | Atherosclerotic cardiovascular disease (ASCVD) | Phase 3 | Trial Planned | Intravenous | Cardiology |